LivaNova PLC (NASDAQ:LIVN) Stake Boosted by Capital Research Global Investors

Capital Research Global Investors increased its position in shares of LivaNova PLC (NASDAQ:LIVN) by 19.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,612,818 shares of the company’s stock after acquiring an additional 258,730 shares during the period. Capital Research Global Investors owned about 2.97% of LivaNova worth $74,690,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. Russell Investments Group Ltd. raised its holdings in shares of LivaNova by 17.1% during the 4th quarter. Russell Investments Group Ltd. now owns 1,502 shares of the company’s stock valued at $70,000 after purchasing an additional 219 shares in the last quarter. Sterling Capital Management LLC lifted its position in shares of LivaNova by 800.6% in the fourth quarter. Sterling Capital Management LLC now owns 1,621 shares of the company’s stock worth $75,000 after buying an additional 1,441 shares during the last quarter. Central Pacific Bank Trust Division boosted its stake in shares of LivaNova by 21.2% during the 4th quarter. Central Pacific Bank Trust Division now owns 4,117 shares of the company’s stock worth $191,000 after acquiring an additional 720 shares in the last quarter. Vestcor Inc acquired a new position in shares of LivaNova during the 4th quarter valued at about $204,000. Finally, Optimize Financial Inc bought a new position in shares of LivaNova in the 4th quarter valued at approximately $208,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

LivaNova Stock Down 2.7 %

Shares of LIVN opened at $34.61 on Tuesday. LivaNova PLC has a 52 week low of $32.48 and a 52 week high of $64.48. The firm has a market capitalization of $1.88 billion, a P/E ratio of 82.40 and a beta of 0.90. The company has a 50-day simple moving average of $39.82 and a 200-day simple moving average of $46.53. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Barclays lowered their price target on LivaNova from $58.00 to $56.00 and set an “equal weight” rating on the stock in a report on Friday, March 7th. Mizuho decreased their price target on shares of LivaNova from $70.00 to $60.00 and set an “outperform” rating for the company in a report on Wednesday, February 26th. StockNews.com upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Tuesday, March 25th. Stifel Nicolaus decreased their target price on LivaNova from $72.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday, February 26th. Finally, Wolfe Research lowered LivaNova from an “outperform” rating to a “peer perform” rating in a report on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating, five have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average target price of $61.17.

LivaNova Company Profile

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.